Zhejiang Huahai Pharmaceutical (600521.SH): publicly listed transfer of innovative drug product Hydrochloride Hydroxyzine tablets innovative R&D technology results.

Zhejiang Huahai Pharmaceutical (600521.SH) announced that the company and the Military Science Institute have entrusted Rongtong Research Institute to transfer the ownership rights of patents, technological achievements, and other related interests of the HHT101 project developed in collaboration with the Military Science Institute through the China Technology Exchange in an open listing manner. The listing price of this transfer is determined through negotiations between the company and the Military Science Institute based on the assessment of the interests enjoyed by both parties, the previous research and development investment, and the progress of future research and development. The final transaction amount will be based on the actual transaction price. After the transfer is completed, the company will no longer pursue the subsequent development of the HHT101 project and will no longer have any rights to the subsequent development of the HHT101 project.